Antihemophilic factor (recombinant), PEGylated-aucl (Jivi)
Antihemophilic factor (recombinant), PEGylated-aucl is an FDA-licensed reference biologic from Bayer HealthCare LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2018
Reference approved
Reference product
Jivi Antihemophilic factor (recombinant), PEGylated-aucl
Bayer HealthCare LLC
- Approved
- Aug 29, 2018
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Antihemophilic factor (recombinant), PEGylated-aucl, in chronological order.
Reference approval
Approval date of the reference Antihemophilic factor (recombinant), PEGylated-aucl product.
7 yr 10 mo ago
Frequently asked questions
Are there biosimilars approved for Antihemophilic factor (recombinant), PEGylated-aucl (Jivi)?
No 351(k) biosimilars or interchangeable biosimilars referencing Antihemophilic factor (recombinant), PEGylated-aucl are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.